XML 33 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Ordinary Shares
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Ordinary Shares

10.  Ordinary Shares

2021

Equity Method and Other Investments

As discussed in Note 3, on January 4, 2021, the Company issued 75,000 ordinary shares in connection with the Visiogene transaction in the amount of $1.2 million.

Acquisitions

As discussed in Note 3, on October 4, 2021 the Company issued 12,040 ordinary shares in connection with the Bullseye acquisition.

Also discussed in Note 3, on October 9, 2021, the Company issued 58,000 ordinary shares in connection with the Emrys acquisition.

2020

Public Offering

In November 2020, the Company issued 5,000,000 ordinary shares in a public offering for gross proceeds of $64.3 million. In December 2020, the underwriter exercised its overallotment provision and the Company issued an additional 750,000 ordinary shares for gross proceeds of $9.6 million. Offering costs in connection with both issuances were approximately $4.6 million.

At-the-Market Offering

In July 2019, the Company entered into an “at-the-market” sales agreement with Chardan Capital Markets, LLC, or Chardan, pursuant to which the Company may sell from time to time, ordinary shares having an aggregate offering price of up to $75.0 million through Chardan, acting as our agent. During the year ended December 31, 2020, the Company raised gross proceeds of $13.2 million, through the sale of 993,448 ordinary shares pursuant to an “at-the-market” equity offering program. Offering costs were approximately $0.5 million. In November 2020, the Company terminated the at-the-market equity program.

Acquisitions

In April 2020, the Company issued 522,000 ordinary shares in connection with the acquisition of Emrys.

In October 2020, the Company issued 22,500 ordinary shares, which represented the holdback shares from a previous acquisition.